Skip to main content
NewslettersWatchlist

Pharming Group N.V. ADR(PHAR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.27
Day High9.59
Open:9.40
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Pharming Group to participate in September investor conferences
PR Newswire
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
PR Newswire
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
PR Newswire
Pharming Group to report second quarter and first half 2023 financial results on August 3
PR Newswire
Pharming announces sale of priority review voucher
PR Newswire
Pharming Group to attend the following Investor Conferences in June
PR Newswire
Pharming Group reports financial results for the first quarter of 2023
PR Newswire
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023
PR Newswire
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023
PR Newswire
Notice of First Quarter 2023 Results
PR Newswire
Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Newswire.ca
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
PR Newswire
Pharming Group convenes the Annual General Meeting of Shareholders 2023
PR Newswire
Pharming Group announces the filing of its 2022 Annual Report and Form 20-F
PR Newswire
Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days
PR Newswire
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
PR Newswire
Pharming Group reports financial results for full year 2022
PR Newswire
Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement
PR Newswire
Notice of Full Year 2022 financial results
Newswire.ca
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
PR Newswire
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
Newswire.ca
Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
PR Newswire
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
PR Newswire
Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting
PR Newswire
Pharming to attend Credit Suisse 31st Annual Healthcare Conference
PR Newswire
Pharming to present at Jefferies Healthcare Conference
PR Newswire
Pharming to present at Stifel Healthcare Conference
Newswire.ca
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
PR Newswire
Pharming Group reports earnings for the first nine months of 2022
PR Newswire
Pharming Group Notice of Q3 Results
Newswire.ca
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Newswire.ca
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Profile

Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The company's product portfolio includes C1INH. Pharming Group N.V. is based in Leiden, The Netherlands.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.